Literature DB >> 19415697

Nuclear cyclin D1: an oncogenic driver in human cancer.

Jong Kyong Kim1, J Alan Diehl.   

Abstract

Perturbations in the regulation of the core cell cycle machinery are frequently observed in human cancers. Cyclin D1 which functions as a mitogenic sensor and allosteric activator of CDK4/6, is one of the more frequently altered cell cycle regulators in cancers. Cyclin D1 is frequently overexpressed in cancers and its overexpression can be attributed to many factors including increased transcription, translation, and protein stability. Although cyclin D1 overexpression is clearly implicated in the affected cancers, overexpression of cyclin D1 is not sufficient to drive oncogenic transformation. Rather, emerging evidence suggests that nuclear retention of cyclin D1 resulting from altered nuclear trafficking and proteolysis is critical for the manifestation of its oncogenicity. This review provides a brief overview of current data documenting various mechanisms underlying aberrant cyclin D1 regulation in human cancers and their impact on neoplastic transformation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19415697      PMCID: PMC2874239          DOI: 10.1002/jcp.21791

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  61 in total

Review 1.  Linking cyclins to transcriptional control.

Authors:  Olivier Coqueret
Journal:  Gene       Date:  2002-10-16       Impact factor: 3.688

2.  Cyclin D1 overexpression in esophageal dysplasia: a possible biomarker for carcinogenesis of esophageal squamous cell carcinoma.

Authors:  A Shamma; Y Doki; H Shiozaki; T Tsujinaka; M Yamamoto; M Inoue; M Yano; M Monden
Journal:  Int J Oncol       Date:  2000-02       Impact factor: 5.650

3.  Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity.

Authors:  Christin E Petre; Yelena B Wetherill; Mark Danielsen; Karen E Knudsen
Journal:  J Biol Chem       Date:  2001-11-19       Impact factor: 5.157

4.  New functional activities for the p21 family of CDK inhibitors.

Authors:  J LaBaer; M D Garrett; L F Stevenson; J M Slingerland; C Sandhu; H S Chou; A Fattaey; E Harlow
Journal:  Genes Dev       Date:  1997-04-01       Impact factor: 11.361

5.  Specific protection against breast cancers by cyclin D1 ablation.

Authors:  Q Yu; Y Geng; P Sicinski
Journal:  Nature       Date:  2001-06-28       Impact factor: 49.962

6.  Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies.

Authors:  T Sonoki; L Harder; D E Horsman; L Karran; I Taniguchi; T G Willis; S Gesk; D Steinemann; E Zucca; B Schlegelberger; F Solé; A J Mungall; R D Gascoyne; R Siebert; M J Dyer
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

7.  Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II.

Authors:  M Jin; S Inoue; T Umemura; J Moriya; M Arakawa; K Nagashima; H Kato
Journal:  Lung Cancer       Date:  2001-11       Impact factor: 5.705

8.  Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation.

Authors:  J R Alt; J L Cleveland; M Hannink; J A Diehl
Journal:  Genes Dev       Date:  2000-12-15       Impact factor: 11.361

9.  A mouse model of human oral-esophageal cancer.

Authors:  Oliver G Opitz; Hideki Harada; Yasir Suliman; Ben Rhoades; Norman E Sharpless; Ralph Kent; Levy Kopelovich; Hiroshi Nakagawa; Anil K Rustgi
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

Review 10.  Chromosome translocations in multiple myeloma.

Authors:  P L Bergsagel; W M Kuehl
Journal:  Oncogene       Date:  2001-09-10       Impact factor: 9.867

View more
  168 in total

1.  Distribution of CCND1 A870G polymorphism in patients with advanced uterine cervical carcinoma.

Authors:  Teresa Warchoł; Lukasz Kruszyna; Margarita Lianeri; Andrzej Roszak; Paweł P Jagodziński
Journal:  Pathol Oncol Res       Date:  2010-08-03       Impact factor: 3.201

Review 2.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Authors:  Patricia Pérez-Galán; Martin Dreyling; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

3.  Over-expressed human TREK-1 inhibits CHO cell proliferation via inhibiting PKA and p38 MAPK pathways and subsequently inducing G1 arrest.

Authors:  Man Zhang; Hua-Jing Yin; Wei-Ping Wang; Jiang Li; Xiao-Liang Wang
Journal:  Acta Pharmacol Sin       Date:  2016-07-11       Impact factor: 6.150

4.  Akt activation by Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells.

Authors:  Angela M Gocher; Gissou Azabdaftari; Lindsey M Euscher; Shuhang Dai; Loukia G Karacosta; Thomas F Franke; Arthur M Edelman
Journal:  J Biol Chem       Date:  2017-06-20       Impact factor: 5.157

5.  Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer.

Authors:  Lei Nie; Hsing-Ju Wu; Jung-Mao Hsu; Shih-Shin Chang; Adam M Labaff; Chia-Wei Li; Yan Wang; Jennifer L Hsu; Mien-Chie Hung
Journal:  Am J Transl Res       Date:  2012-04-08       Impact factor: 4.060

6.  Nuclear accumulation of cyclin D1 following long-term fractionated exposures to low-dose ionizing radiation in normal human diploid cells.

Authors:  Tsutomu Shimura; Nobuyuki Hamada; Megumi Sasatani; Kenji Kamiya; Naoki Kunugita
Journal:  Cell Cycle       Date:  2014-02-14       Impact factor: 4.534

7.  Cyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A/B-dependent BRCA2 phosphorylation.

Authors:  C Chalermrujinanant; W Michowski; G Sittithumcharee; F Esashi; S Jirawatnotai
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

8.  A novel role of IKKalpha in the mediation of UVB-induced G0/G1 cell cycle arrest response by suppressing Cyclin D1 expression.

Authors:  Lun Song; Wen Dong; Ming Gao; Jingxia Li; Meiru Hu; Ning Guo; Chuanshu Huang
Journal:  Biochim Biophys Acta       Date:  2010-01-15

9.  The transcription factor DEC1 (BHLHE40/STRA13/SHARP-2) is negatively associated with TNM stage in non-small-cell lung cancer and inhibits the proliferation through cyclin D1 in A549 and BE1 cells.

Authors:  Yang Liu; Liang Wang; Xu-Yong Lin; Jian Wang; Juan-Han Yu; Yuan Miao; En-Hua Wang
Journal:  Tumour Biol       Date:  2013-02-20

10.  CCND1 G870A polymorphism is associated with toxicity of methotrexate in childhood acute lymphoblastic leukemia.

Authors:  Yao Xue; Liucheng Rong; Na Tong; Meilin Wang; Zhengdong Zhang; Yongjun Fang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.